OPENAI RESEARCHER LAUNCHES DRUG DISCOVERY STARTUP

Wang's work at OpenAI centered on leveraging artificial intelligence to speed up biological and scientific research—expertise that directly applies to his new venture in pharmaceutical development. The funding round, if completed as discussed, would value the startup at $2 billion while raising $200 million in capital. This puts the company in the upper echelon of recently launched biotech-focused AI startups. Wang joins a growing exodus of AI talent launching ventures in drug discovery, a sector increasingly viewed as a high-impact application for large language models and machine learning. Several former researchers from major AI labs have started similar companies in recent years, citing the potential to accelerate drug development timelines and reduce research costs. OpenAI has seen multiple departures recently as researchers pursue both independent projects and roles at competing labs. The company has not commented on Wang's departure.